There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer.
Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.
Written by:
Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Parker CC, Ritchie AW, Russell JM, Thalmann G, Cassoly E, Millman R, Matheson D, Schiavone F, Spears MR, Parmar MK, James ND. Are you the author?
The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK; Medical Research Council Clinical Trials Unit at University College London, London, UK; Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK; University of Bern, Bern, Switzerland; 6Medical Research Council Clinical Trials Unit at University College London, London, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; Department of Urology, University Hospital, Bern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Patient representative, Stockton-on-Tees, UK; Patient representative, Northampton, UK; University of Warwick, Warwick, UK.
Reference: Epub ahead of print.
doi: 10.1016/j.eururo.2014.05.038
PubMed Abstract
PMID: 24985962
UroToday.com Prostate Cancer Section
